Entos Pharmaceuticals Awarded $4 Million USD in Funding from the California Institute for Regenerative Medicine (CIRM) for its Congenital Generalized Lipodystrophy Program
February 05, 2025 11:10 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Entos® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their…